BridgeMD
New treatment option for Laryngeal Disease
Official title Comparison of Remimazolam and Propofol for Recovery of Ambulatory Upper Airway Surgery
ClinicalTrials.gov ID: NCT06507202
What this study is testing
What is Remimazolam?
Remimazolam is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for laryngeal disease.
Also referred to as Byfavo.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to compare the effects of remimazolam and propofol on postoperative recovery time, complications, and safety in patients undergoing ambulatory upper airway surgery under general anesthesia.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- Adult patients (age 19 or older) undergoing ambulatory upper respiratory tract (nasal cavity, oral cavity, pharynx, larynx) surgery under general...
- American Society of Anesthesiologists physical class classification I, II, and III
You likely can't join if
- Patients who refused to participate in the study
- Pregnant patients
- Patients with a history of hypersensitivity to drugs or additives used during surgery
- Patients with acute narrow-angle glaucoma
- Alcohol or drug dependent patients
- Patients with Child-Pugh class C liver dysfunction
The study team makes the final eligibility decision.
Where it's taking place
- Gyeonggi-do, Gwangmyeon-si, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Gyeonggi-do, Gwangmyeon-si, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.